Optimizing Highmark Prior Authorization for Gastroenterology

Highmark Prior Authorization Channels for GI Services

Highmark routes most medical-benefit prior authorization requests for commercial and Medicare Advantage plans through Availity Essentials. X12 278 transactions are also accepted via clearinghouses for impacted procedures. Pharmacy benefit medications, including many specialty GI drugs, may follow separate PBM channels, requiring specific workflow adaptation.

Key Gastroenterology Services Requiring Highmark PA

• IBD Biologics: Agents like Humira, Stelara, Skyrizi, Entyvio, and their biosimilars for Crohn's disease and ulcerative colitis.
• Advanced Imaging: MRCP, MR enterography, and CT enterography for complex GI conditions.
• Endoscopic Procedures: Specific PA requirements for capsule endoscopy (CPT 91110), small-bowel enteroscopy, ERCP, and EUS.
• Hepatitis C DAAs: Medications such as Epclusa and Mavyret, with pathways varying by treatment history.
• Specialty Functional GI Drugs: Including Viberzi, Motegrity, Linzess, and Trulance.
• Non-Routine Colonoscopies: For high-risk surveillance or post-polypectomy follow-up.

Navigating Highmark's Clinical Policies and Documentation for GI

Highmark publishes its medical policies and clinical utilization management guidelines on its provider site, which align with established frameworks like ACG, AGA, and AASLD guidelines. For GI biologics, this often means strict adherence to step therapy protocols, documentation of disease severity (e.g., Mayo score, CDAI), and evidence of prior conventional therapy trials. Missing documentation for pre-treatment screenings (TB, hepatitis) is a common reason for initial denials.

Common Highmark Prior Authorization Denial Reasons in GI

• Step Therapy Non-Compliance: Failure to document trials of conventional therapies or adherence to required biologic sequencing (e.g., TNF before non-TNF agents).
• Biosimilar Mandates: Denials for brand-name biologics when a biosimilar is mandated by Highmark's policy.
• Inadequate Disease Severity Documentation: Missing or incomplete Mayo scores, CDAI, or other objective measures of disease activity for IBD.
• Missing Pre-Biologic Screenings: Lack of documented TB or hepatitis screening results prior to initiating biologic therapy.
• Hepatitis C DAA Specifics: Gaps in documenting fibrosis stage, genotype, or drug-drug interaction reviews.
• Indication Mismatch for Procedures: Clinical indication for advanced imaging or capsule endoscopy not meeting Highmark’s medical necessity criteria.

Klivira's Approach to Highmark GI Prior Authorization

Klivira integrates directly with EMRs to automate the complex workflow of Highmark prior authorizations for gastroenterology. Our platform incorporates ACG/AGA-guideline-aware step therapy logic for IBD biologics, automates treatment-status classification from medication histories, and streamlines documentation for Hep C DAAs, including genotype and fibrosis stage. This ensures submissions meet Highmark's specific requirements, reducing manual burden and denial rates.

Turnaround Times and Escalation Considerations

Highmark's prior authorization turnaround times are subject to state-specific regulations across Pennsylvania, West Virginia, Delaware, and New York. For Medicare Advantage, Medicaid managed care, and Qualified Health Plans on the FFM, Highmark is also impacted by CMS-0057-F, which mandates specific electronic prior authorization requirements and timelines. Practices should establish clear internal protocols for tracking these timelines and initiating peer-to-peer discussions when medically appropriate.